{"id":1330,"date":"2025-02-04T14:06:58","date_gmt":"2025-02-04T13:06:58","guid":{"rendered":"https:\/\/www.sunrockbiopharma.com\/?p=1330"},"modified":"2025-02-13T11:13:44","modified_gmt":"2025-02-13T10:13:44","slug":"sunrock-biopharma-realizara-una-presentacion-oral-sobre-su-anticuerpo-anti-ccr9-para-la-eii-en-ecco25-berlin","status":"publish","type":"post","link":"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-realizara-una-presentacion-oral-sobre-su-anticuerpo-anti-ccr9-para-la-eii-en-ecco25-berlin\/","title":{"rendered":"SunRock Biopharma realizar\u00e1 una presentaci\u00f3n oral sobre su anticuerpo anti-CCR9 para la EII en ECCO25, Berl\u00edn."},"content":{"rendered":"
La comunicaci\u00f3n de SunRock ha sido seleccionada para su presentaci\u00f3n oral en el 20\u00ba Congreso de ECCO, que se celebrar\u00e1 del 19 al 22 de febrero de 2025 en Berl\u00edn (Alemania).<\/p>\n
DOP065 SRB1: a Best-in-Class CCR9 depleting antibody that restores immune homeostasis in IBD patients<\/p>\n